Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.

Akamandisa MP, Nie K, Nahta R, Hambardzumyan D, Castellino RC.

Neuro Oncol. 2019 Mar 10. pii: noz053. doi: 10.1093/neuonc/noz053. [Epub ahead of print]

PMID:
30852603
2.

Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition.

Taylor IC, Hütt-Cabezas M, Brandt WD, Kambhampati M, Nazarian J, Chang HT, Warren KE, Eberhart CG, Raabe EH.

J Neuropathol Exp Neurol. 2015 Aug;74(8):778-90. doi: 10.1097/NEN.0000000000000216.

3.

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.

Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R.

BMC Cancer. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.

4.

Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.

Sewing ACP, Lagerweij T, van Vuurden DG, Meel MH, Veringa SJE, Carcaboso AM, Gaillard PJ, Peter Vandertop W, Wesseling P, Noske D, Kaspers GJL, Hulleman E.

J Neurosurg Pediatr. 2017 May;19(5):518-530. doi: 10.3171/2016.9.PEDS16152. Epub 2017 Feb 17.

PMID:
28291423
5.

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G, Le Dret L, Richon C, Lacroix L, Puget S, Geoerger B, Vassal G, Östman A, Grill J.

Neuro Oncol. 2015 Jul;17(7):953-64. doi: 10.1093/neuonc/nou330. Epub 2014 Dec 21.

6.

Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.

Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C.

Mol Cancer Ther. 2015 Nov;14(11):2560-8. doi: 10.1158/1535-7163.MCT-15-0282. Epub 2015 Sep 8.

7.

The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.

Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH.

Cancer Lett. 2017 Aug 1;400:110-116. doi: 10.1016/j.canlet.2017.04.019. Epub 2017 Apr 25.

8.

Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.

Sun Y, Sun Y, Yan K, Li Z, Xu C, Geng Y, Pan C, Chen X, Zhang L, Xi Q.

EBioMedicine. 2019 May 3. pii: S2352-3964(19)30282-8. doi: 10.1016/j.ebiom.2019.04.043. [Epub ahead of print]

9.

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.

Esfandiari A, Hawthorne TA, Nakjang S, Lunec J.

Mol Cancer Ther. 2016 Mar;15(3):379-91. doi: 10.1158/1535-7163.MCT-15-0651. Epub 2016 Feb 1.

10.

Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.

Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, Chang C, Gifford AJ, Tsoli M, Ziegler DS, Carcaboso AM, Becher OJ.

PLoS One. 2017 Jan 4;12(1):e0169485. doi: 10.1371/journal.pone.0169485. eCollection 2017.

11.

A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.

Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, Crabtree DM, Cordero FJ, Singh R, Spasojevic I, Berlow N, Pal R, Becher OJ.

PLoS One. 2015 Mar 6;10(3):e0118926. doi: 10.1371/journal.pone.0118926. eCollection 2015.

12.

The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.

Kojima K, Maeda A, Yoshimura M, Nishida Y, Kimura S.

Oncotarget. 2016 Oct 25;7(43):69625-69637. doi: 10.18632/oncotarget.11904.

13.

Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma.

Zhang Y, Dong W, Zhu J, Wang L, Wu X, Shan H.

Cell Biosci. 2017 Oct 30;7:56. doi: 10.1186/s13578-017-0184-0. eCollection 2017.

14.

Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.

Gits HC, Anderson M, Stallard S, Pratt D, Zon B, Howell C, Kumar-Sinha C, Vats P, Kasaian K, Polan D, Matuszak M, Spratt DE, Leonard M, Qin T, Zhao L, Leach J, Chaney B, Escorza NY, Hendershot J, Jones B, Fuller C, Leary S, Bartels U, Bouffet E, Yock TI, Robertson P, Mody R, Venneti S, Chinnaiyan AM, Fouladi M, Gottardo NG, Koschmann C.

Acta Neuropathol Commun. 2018 Jul 26;6(1):67. doi: 10.1186/s40478-018-0570-9.

15.

The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.

Anderson JL, Muraleedharan R, Oatman N, Klotter A, Sengupta S, Waclaw RR, Wu J, Drissi R, Miles L, Raabe EH, Weirauch ML, Fouladi M, Chow LM, Hoffman L, DeWire M, Dasgupta B.

Neuro Oncol. 2017 Aug 1;19(8):1068-1078. doi: 10.1093/neuonc/now299.

16.

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.

Qi J, Esfahani DR, Huang T, Ozark P, Bartom E, Hashizume R, Bonner ER, An S, Horbinski CM, James CD, Saratsis AM.

Acta Neuropathol Commun. 2019 May 15;7(1):75. doi: 10.1186/s40478-019-0727-1.

17.

Human pontine glioma cells can induce murine tumors.

Caretti V, Sewing AC, Lagerweij T, Schellen P, Bugiani M, Jansen MH, van Vuurden DG, Navis AC, Horsman I, Vandertop WP, Noske DP, Wesseling P, Kaspers GJ, Nazarian J, Vogel H, Hulleman E, Monje M, Wurdinger T.

Acta Neuropathol. 2014;127(6):897-909. doi: 10.1007/s00401-014-1272-4. Epub 2014 Apr 29.

18.

Targeting Wee1 for the treatment of pediatric high-grade gliomas.

Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2014 Mar;16(3):352-60. doi: 10.1093/neuonc/not220. Epub 2013 Dec 4.

19.

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.

Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WG, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS.

Cancer Manag Res. 2018 Sep 12;10:3483-3500. doi: 10.2147/CMAR.S167095. eCollection 2018.

20.

Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology.

Schroeder KM, Hoeman CM, Becher OJ.

Pediatr Res. 2014 Jan;75(1-2):205-9. doi: 10.1038/pr.2013.194. Epub 2013 Nov 5. Review.

PMID:
24192697

Supplemental Content

Support Center